Company intelligence / Profile preview

Genaderm

Florham Park, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Genaderm was a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare dermatological diseases. The company's lead program, CCP-020, was a topical formulation of diacerein, a small molecule inhibitor of interleukin-1 beta, designed to treat epidermolysis bullosa simplex (EBS). In September 2016, Genaderm was acquired by Castle Creek Pharmaceuticals (now Castle Creek Biosciences). This acquisition integrated Genaderm's EBS program into Castle Creek's pipeline of therapies for orphan skin disorders. The company was founded by the experienced drug development team that previously founded Pharmasset, the developer of the hepatitis C drug Sovaldi.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Genaderm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genaderm.

Explore the full profile